Ceftazidime

Common Uses

Ceftazidime is prescribed to treat various types of infections caused by bacteria. It is often used for serious or life-threatening conditions, including:

• Respiratory infections: Such as pneumonia and other infections of the lower respiratory tract.
• Skin infections: Including infections of the skin and the tissues just beneath the skin.
• Urinary tract infections: Both complicated and uncomplicated infections of the bladder or kidneys.
• Bloodstream infections: Such as bacterial septicemia (blood poisoning).
• Bone and joint infections: To treat bacterial growth in the skeletal system.
• Abdominal infections: Including infections within the abdominal cavity and gynecological infections.
• Central nervous system infections: Such as meningitis, which is an infection of the membranes surrounding the brain and spinal cord.

Other Uses

Healthcare providers may also use ceftazidime as an initial treatment for patients who have a fever and a very low white blood cell count, a condition known as febrile neutropenia. This is often done when the risk of a serious bacterial infection is high.

It is important to note that ceftazidime only treats bacterial infections. It will not work for viral infections, such as the common cold, the flu, or most coughs and sore throats.

Mechanism of Action

Ceftazidime belongs to a class of medications known as cephalosporin antibiotics. It works by preventing bacteria from growing and multiplying within the body.

To survive, bacteria must build and maintain a protective outer layer called a cell wall. Ceftazidime interferes with the final stages of this construction process. By binding to specific proteins, the medication prevents the bacteria from creating a stable wall. This causes the cell wall to break down, leading to the death of the bacteria.

Targeted Infections

This antibiotic is effective against many different types of bacteria, particularly those referred to as Gram-negative bacteria. It is important to remember that ceftazidime only treats bacterial infections; it does not work for viral infections like the common cold or the flu.

Common Side Effects

Common side effects of ceftazidime may include:

• Pain, redness, or swelling at the injection site
• Nausea or vomiting
• Diarrhea
• Stomach pain
• Headache
• Dizziness
• Numbness or tingling
• Vaginal itching or discharge

Serious Side Effects

Seek medical attention immediately if you experience any of the following serious side effects:

• Allergic reactions: Symptoms such as skin rash, hives, itching, or swelling of the face, lips, or throat.
• Severe diarrhea: Watery or bloody stools, which may be accompanied by stomach cramps or fever. This can occur during treatment or up to several months after the last dose.
• Neurological issues: Seizures, tremors, or muscle twitching, particularly in patients with kidney problems.
• Skin reactions: Blistering or peeling skin.
• Liver or kidney changes: Yellowing of the eyes or skin, dark urine, or a significant change in how much you urinate.
• Unusual bleeding: Easy bruising or bleeding that does not stop quickly.

Allergic Reactions

Serious and occasionally fatal hypersensitivity (allergic) reactions have been reported. Before starting treatment, it is important to determine if there is a history of hypersensitivity to ceftazidime, other cephalosporins, penicillins, or other drugs. If an allergic reaction occurs, the medication must be discontinued immediately.

Neurological Risks

Neurological complications, including seizures, encephalopathy (brain dysfunction), and involuntary muscle twitching, can occur. These risks are higher in patients with kidney impairment who do not receive appropriate dose adjustments. Monitoring kidney function is often necessary during treatment.

Diarrhea and Intestinal Issues

Nearly all antibacterial agents, including ceftazidime, can cause Clostridioides difficile-associated diarrhea (CDAD). This condition can range in severity from mild diarrhea to life-threatening inflammation of the colon. It may occur during treatment or several months after the medication has stopped.

Kidney Function

The total daily dosage of ceftazidime should be reduced in patients with temporary or permanent decreases in kidney function. High or prolonged blood levels of the drug in these patients can lead to seizures and other neurological issues. Concurrent use of other medications that may affect the kidneys, such as aminoglycosides or potent diuretics, may increase the risk of kidney toxicity.

Other Precautions

• Superinfection: Long-term use may lead to the overgrowth of organisms that are not sensitive to the medication.
• Drug Resistance: Using ceftazidime when a bacterial infection is not strongly suspected increases the risk that bacteria will become resistant to the drug.
• Interference with Lab Tests: This medication may cause a false-positive result in certain urine glucose tests.

Pregnancy

There are no adequate and well-controlled studies of ceftazidime use in pregnant women. Animal reproduction studies using high doses have not shown evidence of impaired fertility or harm to the fetus. Because animal studies are not always predictive of human response, this medication should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breastfeeding

Ceftazidime is excreted in human milk in low concentrations. While the amount is small, it may potentially affect the nursing infant. Possible concerns include:

• Changes in the infant's natural gut bacteria, which may lead to diarrhea.
• The development of fungal infections, such as thrush.
• The risk of an allergic reaction if the infant is sensitive to cephalosporin antibiotics.

Healthcare providers typically exercise caution when prescribing ceftazidime to individuals who are breastfeeding. It is important to discuss the potential risks and benefits with a doctor to determine the best course of action for both the parent and the infant.

Available Forms

Ceftazidime is available as an injectable medication. It is typically supplied in the following formats:

• Powder for Injection: This form is provided in vials and must be reconstituted with a compatible liquid before administration. It may be given by intravenous injection or infusion, or by intramuscular injection.
• Premixed Intravenous Solution: This form is supplied as a frozen or ready-to-use solution in infusion containers for intravenous use only.

FDA Approval and Indications

Ceftazidime is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several types of infections caused by susceptible bacteria. These include:

• Lower respiratory tract infections, such as pneumonia.
• Skin and skin-structure infections.
• Urinary tract infections, both complicated and uncomplicated.
• Bacterial septicemia (bloodstream infections).
• Bone and joint infections.
• Gynecological infections, including endometritis and pelvic cellulitis.
• Intra-abdominal infections, such as peritonitis.
• Central nervous system infections, including meningitis.

Regulatory Status

Ceftazidime is available only by prescription. It is typically administered in a healthcare setting via intravenous (IV) or intramuscular (IM) injection. While there are no boxed warnings for this medication, the FDA requires manufacturers to include warnings regarding the potential for severe hypersensitivity (allergic) reactions, particularly in patients with a history of penicillin allergy. Additionally, like most antibiotics, it carries a warning for Clostridioides difficile-associated diarrhea, which can range in severity from mild diarrhea to fatal colitis.

FDA-Approved Indications

Ceftazidime is approved by the U.S. Food and Drug Administration (FDA) to treat several types of infections caused by susceptible strains of bacteria. These indications include:

• Lower respiratory tract infections: Including pneumonia.
• Skin and skin structure infections: Such as infected wounds or ulcers.
• Urinary tract infections: Both complicated and uncomplicated cases.
• Bacterial septicemia: Serious infections of the bloodstream.
• Bone and joint infections: Including osteomyelitis.
• Gynecological infections: Such as endometritis and pelvic cellulitis.
• Intra-abdominal infections: Including peritonitis.
• Central nervous system infections: Including bacterial meningitis.

Regulatory Status and Administration

Ceftazidime is a prescription-only medication. The FDA has approved its administration via intravenous (IV) infusion or intramuscular (IM) injection. It is typically used in clinical settings where patients can be monitored by healthcare professionals.

Pediatric and Combination Approvals

The FDA has approved ceftazidime for use in pediatric patients, including neonates and infants. Additionally, the FDA has approved a combination product containing ceftazidime and avibactam. This combination is specifically indicated for treating complicated intra-abdominal infections and complicated urinary tract infections in patients with limited treatment options.